Amazing what a CR can do to get a bit of attention from Investors, so close to inflection points @ Eqz. Many a time in biotechs, it doesn’t do much after the pump, but this is a bit different this time; with Orphan Status & only one trial required on a Ph3 for that in FSGS if Ph2 successful (you have to add that even though they have been to the FDA recently for IND on a Ph3), & other indications that can be applied for with market exclusivity on top of patents (DKD).
Very attractive to Big Pharma, both for safety & efficacy in a clinically unmet need. Both indications, because our numbers are better in Ph2A from diabetes & no SAEs, unlike Invokana. (PIQ have a collaboration with for PromarkerD, Janssen, J&J), the first drug to be approved by the FDA in the last 20yrs for DKD, & DXB have a licensing agreement on PromarkerD too.
The drug is already speaking for efficacy anyway with Ph2A patients remaining on it from SAS (Special Access Scheme with TGA).
Feel like I’m repeating myself, but there are a few important ‘differences’ here in this stock for holders of Ph2 biotechs, IP & status with the FDA. A very professional & forward thinking company. Do your own DD people. There is no need to say more.
GLTAH
- Forums
- ASX - By Stock
- Taylor's Initiation
Amazing what a CR can do to get a bit of attention from...
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $164.5M |
Open | High | Low | Value | Volume |
31.0¢ | 31.0¢ | 30.0¢ | $818.6K | 2.683M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 1874183 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 10850 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1874183 | 0.300 |
8 | 282104 | 0.295 |
16 | 1221907 | 0.290 |
8 | 239548 | 0.285 |
8 | 222379 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 10850 | 1 |
0.310 | 277820 | 4 |
0.315 | 291993 | 6 |
0.320 | 529798 | 8 |
0.325 | 144810 | 6 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
30.0¢ |
  |
Change
-0.005 ( 1.64 %) |
|||
Open | High | Low | Volume | ||
31.0¢ | 31.0¢ | 30.0¢ | 640607 | ||
Last updated 15.54pm 28/03/2024 ? |
Featured News
DXB (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online